Skip to main content
Retour
Watch Compare

AVENUE THERAPEUTICS, INC.

Qualité des données : 100%
ATXI
OTC Manufacturing Chemicals
0,40 €
▼ 0,05 € (-11,11%)
Cap. Boursière: 1,48 M
Prix
0,45 €
Cap. Boursière
1,48 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -1,83 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-76,40%
En dessous de la moyenne du secteur (-53,47%)
ROIC-94,86%
Net Margin-207,19%
Op. Margin-219,59%

Sécurité

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valorisation

PE (TTM)
-0,51
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,42
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,5 -1,5
P/B 0,4 1,6
ROE % -76,4 -53,5
Net Margin % -207,2 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q32024 -0,94 € -1,92 € -104,3%
Q22024 -1,05 € -2,41 € -129,4%
Q12024 -9,00 € -15,40 € -71,1%
Q42023 -7,50 € 42,00 € +660,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,40 M Net Income (TTM) -2,91 M
ROE -76,40% ROA -73,78%
Gross Margin N/A Operating Margin -219,59%
Net Margin -207,19% Free Cash Flow (TTM) -1,83 M
ROIC -94,86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover 0,36
Working Capital N/A Tangible Book Value 3,56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,51 Forward P/E N/A
P/B Ratio 0,42 P/S Ratio 1,06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -123,64%
Market Cap 1,48 M Enterprise Value -2,23 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0,43
FCF / Share -0,56 OCF / Share -0,56
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 63,01%
SBC-Adj. FCF -2,69 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,40 M — — — —
Net Income -2,91 M -11,70 M -10,49 M -3,55 M -3,73 M
EPS (Diluted) — — — — -0,22
Gross Profit — — — — —
Operating Income -3,08 M -11,28 M -14,54 M -8,04 M -3,74 M
EBITDA — — — — —
R&D Expenses 1,04 M 6,65 M 6,13 M 2,70 M 1,25 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 2 000,0 0,0 0,0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,93 M 2,67 M 1,85 M 6,85 M 3,96 M
Total Liabilities 1,10 M 816 000,0 1,20 M 3,58 M 509 000,0
Shareholders' Equity 1,83 M 2,80 M 1,58 M 3,91 M 3,45 M
Total Debt — — — — —
Cash & Equivalents 2,86 M 2,59 M 1,78 M 6,71 M 3,76 M
Current Assets — — — — 3,96 M
Current Liabilities 1,10 M 816 000,0 1,20 M 3,58 M 509 000,0